Quick Listen: Scrip's Five Must-Know Things
In this week's podcast version of Five Must-Know Things: a US setback for UCB; Lilly challenges Novo’s GLP franchise; Seagen searches for CEO after scandal; Hengrui hopes for US PD-1 success; and a look ahead at ASCO.
Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 20 May 2022, including: a US setback for UCB S.A.; Eli Lilly and Company challenges Novo Nordisk A/S’s GLP franchise; Seagen Inc. searches for CEO after scandal; Jiangsu Hengrui Medicine Co., Ltd. hopes for US PD-1 success; and a look ahead at ASCO.
This and all our other podcasts are available on the Informa Pharma Intelligence channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
(Also see "UCB Rocked By US FDA Rejection Of Blockbuster-In-Waiting Bimzelx" - Scrip, 13 May, 2022.)
(Also see "Lilly’s Mounjaro Diabetes Approval Is First Challenge To Novo’s GLP-1 Franchise" - Scrip, 13 May, 2022.)
(Also see "Seagen CEO Search Under Way As Longtime Leader Siegall Resigns In Scandal" - Scrip, 16 May, 2022.)
(Also see "Hengrui’s PD-1 Camrelizumab Moves Step Closer To US Filing" - Scrip, 16 May, 2022.)
(Also see "Five Late-Breaking Studies To Look Out For At ASCO" - Scrip, 18 May, 2022.)